| DC7265 |
Rigosertib
Featured
|
Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM; shows 30-fold greater selectivity against PLK2 and no activity to PLK3. |
|
| DC8215 |
RO4929097
Featured
|
RO4929097 is a γ secretase inhibitor with IC50 of 4 nM, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively. |
|
| DC7489 |
RO5126766(CH5126766) |
RO5126766(CH5126766) is a Raf/MEK dual kinase inhibitor. |
|
| DC12353 |
Roniciclib (BAY 1000394) |
Roniciclib is an orally bioavailable pan-cyclin dependent kinase (CDK) inhibitor, with IC50s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9. |
|
| DC4124 |
ROSCOVITINE(Seliciclib)
Featured
|
Roscovitine (Seliciclib, CYC202, R-roscovitine) is a potent and selective CDK inhibitor for Cdc2/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p53 with IC50 of 0.65 μM, 0.7 μM, 0.7 μM and 0.16 μM, respectively. |
|
| DC10036 |
RRx-001
Featured
|
RRx-001 is a novel epigenetic modulator with potential radiosensitizing activity. It inhibits glucose 6-phosphate dehydrogenase(G6PD) in human tumor cells, binds hemoglobin and drives RBC-mediated redox reactions under hypoxia. |
|
| DC5151 |
Rucaparib phosphate (AG-14699, PF-01367338)
Featured
|
Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM with binding affinity to nine PARP domains. Phase 1/2. |
|
| DC8464 |
Rucaparib(AG-014447)
Featured
|
Rucaparib inactivates PARP activity in cells with homologous recombination DNA repair pathway mutations at LC50 values ranging from 1.3-5.5 μM. |
|
| DC4230 |
Ruxolitinib (INCB018424)
Featured
|
Ruxolitinib is a potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5 nM, respectively and is relatively less selective for JAK3 (IC50 = 322 nM). |
|
| DC8309 |
Ruxolitinib Phosphate
Featured
|
Ruxolitinib Phosphate is a potent and selective Janus kinase (JAK1, IC50 = 5.9 nM and JAK2, IC50 = 5.7 nM) inhibitor. |
|
| DC7762 |
RX-3117
Featured
|
RX-3117 is an orally available and potent DNA synthesis inhibitor with potential antineoplastic activity. |
|
| DC10479 |
RX518(CK-101:EGFR-IN-3)
Featured
|
RX518(CK-101) is an orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations. |
|
| DC11265 |
S49076 (hydrochloride)
Featured
|
S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. |
|
| DC10071 |
S49076
Featured
|
S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM. |
|
| DC12279 |
S55746 hydrochloride (BLC201 (hydrochloride)) |
S55746 hydrochloride is a potent, orally active and selective BCL-2 inhibitor, with Kis and Kds of 1.3 nM, 520 nM and 3.9 nM, 186 nM for BCL-2 and BCL-XL, respectively. S55746 hydrochloride has antitumor activity. |
|
| DC12163 |
S55746 (BLC201)
Featured
|
S55746 (BLC201) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 (BLC201) has antitumor activity with low toxicity[1]. |
|
| DC10137 |
S63845
Featured
|
S63845 is a potent and selective myeloid cell leukemia 1 (MCL1) inhibitor; binds human MCL1 with a Kd of 0.19 nM. |
|
| DC10444 |
Sapacitabine (CYC682)
Featured
|
Sapacitabine is an orally bioavailable pyrimidine analogue prodrug with potential antineoplastic activity. |
|
| DC7078 |
AZD-8931(Sapitinib)
Featured
|
Sapitinib(AZD8931) is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM respectively. |
|
| DC7672 |
SAR125844
Featured
|
SAR125844 is inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity. |
|
| DC7276 |
Saracatinib (AZD0530)
Featured
|
Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). |
|
| DC12276 |
Saridegib (IPI-926; Patidegib)
Featured
|
Saridegib is a potent and specific inhibitor of Smoothened (Smo), a key signaling transmembrane protein in the Hedgehog (Hh) pathway. |
|
| DC5137 |
SB 743921
Featured
|
SB743921 is a kinesin spindle protein (KSP) inhibitor with Ki of 0.1 nM, almost no affinity to MKLP1, Kin2, Kif1A, Kif15, KHC, Kif4 and CENP-E. |
|
| DC5024 |
MK-8776 (SCH 900776)
Featured
|
SCH 900776 is a selective Chk1 inhibitor with IC50 of 3 nM. It shows 50-fold selectivity against Chk2. Phase 2. |
|
| DC7283 |
SCH-772984
Featured
|
SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 of 4 nM and 1 nM, respectively. |
|
| DC7290 |
Semaxanib (SU5416)
Featured
|
Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM, 20-fold more selective for VEGFR than PDGFRβ, lack of activity against EGFR, InsR and FGFR. |
|
| DC11812 |
SF-1126 |
SF-1126 is a pan PI3K/BRD4 inhibitor, RGDS-conjugated LY294002 prodrug that exhibits increased solubility and binds to specific integrins. |
|
| DC6313 |
Guadecitabine（SGI-110）
Featured
|
SGI-110 (S-110) is a stable and potent inhibitor for DNA methylation, inhibits DNMT1 when SGI-110 is activated by phosphorylation and incorporated into DNA. |
|
| DC7160 |
SGI-1776
Featured
|
SGI-1776 is a novel ATP competitive inhibitor of Pim1 with IC50 of 7 nM; 50- and 10-fold selective versus Pim2 and Pim3, also potent to Flt3 and haspin. |
|
| DC7294 |
SGX-523
Featured
|
SGX-523 is a selective Met inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α. |
|
